Gapping up
In reaction to strong earnings/guidance: BLOX +13.4%, AMBA +9.3%, LOCO +2.9%, VRNT +2.6%.
Other news: PRAN +27.6% (received orphan designation status for its product for the treatment of Huntington's disease), HART +13.7% (received orphan designation status for its inBreath airway transplant system to restore the structure and/or function of the trachea subsequent to tracheal damage due to cancer, injury or infection), NSPH +10.8% (has engaged Jefferies LLC as its financial advisor to assist it in the development and evaluation of a full range of potential strategic alternatives for the Company), TASR +6% (higher following announcement that the NYPD will begin a pilot program of equipping officers with body cameras), OMED +4.1% (FDA removes partial clinical hold on OncoMed's ipafricept), ICLD +2.8% (announces multi-site deployment of security and threat prevention solutions and services for a large global consulting firm), MOBI +2.6% (announces repurchase of 16 mln shares from Sequoia Capital ), GPRO +1.7% (up in sympathy following supplier AMBA earnings), DGLY +1.5% (cont usual volatility pre-mkt), JOY +1% (positive Barron's mention), SD +0.8% ( announces $200 mln share repurchase program)
Analyst comments: IPCI +3.7% (upgraded to Buy at Maxim Group), VRTX +2.3% (upgraded to Buy from Neutral at Goldman), CIEN +1.8% (upgraded to Buy from Neutral at Goldman), ICPT +1.8% (initiated with an Outperform at Cowen), MTRX +1.7% (upgraded to Overweight from Equal Weight at First Analysis Sec), SNDK +1.5% (upgraded to Overweight from Equal-Weight at Morgan Stanley), BLUE +1.4% (initiated with a Buy at Sun Trust Rbsn Humphrey), INSM +1.4% (initiated with an Outperform at Cowen), MBLY +1.4% (target raised to $52 at RBC Capital Mkts), IL +1.1% (upgraded to Buy at Stifel ), ING +1% (upgraded to Overweight from Equal Weight at Barclays), BEAV +1% (upgraded to Buy from Hold at Deutsche Bank), BP +0.9% (upgraded to Buy from Neutral at Citigroup), QGEN +0.6% (upgraded to Buy from Sell at DZ Bank)
In reaction to strong earnings/guidance: BLOX +13.4%, AMBA +9.3%, LOCO +2.9%, VRNT +2.6%.
Other news: PRAN +27.6% (received orphan designation status for its product for the treatment of Huntington's disease), HART +13.7% (received orphan designation status for its inBreath airway transplant system to restore the structure and/or function of the trachea subsequent to tracheal damage due to cancer, injury or infection), NSPH +10.8% (has engaged Jefferies LLC as its financial advisor to assist it in the development and evaluation of a full range of potential strategic alternatives for the Company), TASR +6% (higher following announcement that the NYPD will begin a pilot program of equipping officers with body cameras), OMED +4.1% (FDA removes partial clinical hold on OncoMed's ipafricept), ICLD +2.8% (announces multi-site deployment of security and threat prevention solutions and services for a large global consulting firm), MOBI +2.6% (announces repurchase of 16 mln shares from Sequoia Capital ), GPRO +1.7% (up in sympathy following supplier AMBA earnings), DGLY +1.5% (cont usual volatility pre-mkt), JOY +1% (positive Barron's mention), SD +0.8% ( announces $200 mln share repurchase program)
Analyst comments: IPCI +3.7% (upgraded to Buy at Maxim Group), VRTX +2.3% (upgraded to Buy from Neutral at Goldman), CIEN +1.8% (upgraded to Buy from Neutral at Goldman), ICPT +1.8% (initiated with an Outperform at Cowen), MTRX +1.7% (upgraded to Overweight from Equal Weight at First Analysis Sec), SNDK +1.5% (upgraded to Overweight from Equal-Weight at Morgan Stanley), BLUE +1.4% (initiated with a Buy at Sun Trust Rbsn Humphrey), INSM +1.4% (initiated with an Outperform at Cowen), MBLY +1.4% (target raised to $52 at RBC Capital Mkts), IL +1.1% (upgraded to Buy at Stifel ), ING +1% (upgraded to Overweight from Equal Weight at Barclays), BEAV +1% (upgraded to Buy from Hold at Deutsche Bank), BP +0.9% (upgraded to Buy from Neutral at Citigroup), QGEN +0.6% (upgraded to Buy from Sell at DZ Bank)